Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.

Antimicrob Agents Chemother. 1996 Mar;40(3):750-4. Unique Identifier : AIDSLINE MED/97004294
Datema R; Rabin L; Hincenbergs M; Moreno MB; Warren S; Linquist V; Rosenwirth B; Seifert J; McCune JM; Sandoz Research Institute, Vienna, Austria.

Abstract: SID 791, a bicyclam inhibiting human immunodeficiency virus (HIV) replication in vitro by blocking virus entry into cells, is an effective inhibitor of virus production and of depletion of human CD4+ T cells in HIV type 1-infected SCID-hu Thy/Liv mice. Steady levels of 100 ng of SID 791 or higher per ml in plasma resulted in statistically significant inhibition of p24 antigen formation. Daily injections of SID 791 caused a dose-dependent decrease in viremia, and this inhibition could be potentiated by coadministration of zidovudine or didanose. The present study suggests that SID 791 alone or in combination with licensed antiviral agents may decrease the virus load in HIV-infected patients and, by extension, that the infectious cell entry step is a valid target for antiviral chemotherapy of HIV disease. The SCID-hu Thy/Liv model in effect provides a rapid means of assessing the potential of compounds with novel modes of antiviral action, as well as the potential of antiviral drug combinations.

Keywords: Animal Antiviral Agents/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/ PHARMACOKINETICS Chromatography, High Pressure Liquid CD4-CD8 Ratio/DRUG EFFECTS Didanosine/PHARMACOLOGY Drug Implants Heterocyclic Compounds/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/ PHARMACOKINETICS HIV Infections/PREVENTION & CONTROL/VIROLOGY HIV-1/*DRUG EFFECTS Injections, Subcutaneous Mice Mice, Inbred BALB C Mice, SCID Rats Spectrophotometry, Ultraviolet Support, Non-U.S. Gov't Virus Replication/DRUG EFFECTS Zidovudine/PHARMACOLOGY JOURNAL ARTICLE
97033030
M9730842

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .